Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia
- Conditions
- Stress
- Interventions
- Drug: PlaceboProcedure: Functional MRI
- Registration Number
- NCT06364228
- Lead Sponsor
- University of Nebraska
- Brief Summary
The overall aim of this study is to determine the efficacy and safety of intranasal oxytocin (OXT) to improve the quality of life and reduce chronic stress levels in the caregivers to the persons with dementia. Randomized, double-blind, placebo-controlled clinical trial of intranasal oxytocin (12 or 24 IU) will be conducted by daily administration (once a day) for 21 days (3 weeks).
- Detailed Description
The overall aim of this study is to determine the efficacy and safety of intranasal oxytocin (OXT) to improve the quality of life and reduce chronic stress levels in the caregivers to the persons with dementia. Randomized, double-blind, placebo-controlled clinical trial of intranasal oxytocin (12 or 24 IU) will be conducted by daily administration (once a day) for 21 days (3 weeks).
Endogenous neuropeptide oxytocin (OXT) has been a focus of prior psychiatric research based upon its role in pro-social behavior and modulation of response to social/emotional stimuli. However, currently there is no comprehensive study examining its role in the caregivers to chronic medical/psychiatric illnesses including dementia for potential beneficial impact as well as reducing chronic stress levels.
This study aims to establish intranasal OXT's efficacy and safety for these clinical implications. Investigators will also apply methods (task related functional MRI) that have shown verifiable and measurable ability to capture the core target area (mPFC and amygdala) and its change in response to OXT.
This project will lead to progress in understanding the potential role of OXT on the relationship between caregiver and the person with chronic medical/psychiatric illnesses such as dementia. It will also guide future direction for clinical use of intranasal OXT for this critical population.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Female
- Target Recruitment
- 32
- Females 50 years of age or older
- Currently an unpaid family caregiver to an older adult (50 years and older) with dementia for at least five hours a week for at least six months
- Normal or corrected to normal vision and hearing
- Mobility to travel to University of Nebraska Medical Center (UNMC) for study procedures including brain imaging
- Right-handed
- Capacity to read and write English
- Major medical illness that contraindicates oxytocin (OXT) administration (e.g., severe liver disease, seizure disorder, metabolic disorder)
- History of allergic reaction to oxytocin (OXT) and its nasal spray product
- History of central nervous system (CNS) disease, including history of seizure, epilepsy, CNS tumor, CNS hemorrhage, or serious CNS infection including meningitis or encephalitis
- Currently pregnant or planning to become pregnant during the course of the study
- Metal in the body (i.e., hearing aid, cardiac pacemaker, bone plates, braces, non-removable piercing/implants, etc.), claustrophobia, or any other condition that would preclude magnetic resonance imaging (MRI) scanning
- Mini-mental status exam score of 25 or lower which suggests possible cognitive issues
- History of or current neurological disease (e.g., stroke, traumatic brain injury, brain tumor, dementia)
- History of or current severe psychiatric disease (e.g., schizophrenia, bipolar disorder, autism, severe post-traumatic stress disorder)
- History of, or current drug or alcohol abuse
- Currently breastfeeding
- Current coronavirus disease-19 (COVID-19) illness
- Left-handed due to brain structural difference between right and left-handed individuals
- Currently taking antipsychotic medications, selective serotonin reuptake inhibitors (SSRIs) or corticosteroid creams/pills
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intranasal Spray Placebo Placebo Nasal Spray of placebo liquid solution as 2 puffs of daily dose (every morning) for 3 weeks. Functional magnetic resonance imaging (fMRI) scan pre- and post-administration. Intranasal Spray Placebo Functional MRI Nasal Spray of placebo liquid solution as 2 puffs of daily dose (every morning) for 3 weeks. Functional magnetic resonance imaging (fMRI) scan pre- and post-administration. Oxytocin Intranasal Spray 12 International Unit (IU) Oxytocin Intranasal Spray 12 International Unit (12IU) Nasal spray of Oxytocin 12 International Unit (12IU) liquid solution as 2 puffs of daily dose (every morning) for 3 weeks. Functional magnetic resonance imaging (fMRI) scan pre- and post-administration. Oxytocin Intranasal Spray 12 International Unit (IU) Functional MRI Nasal spray of Oxytocin 12 International Unit (12IU) liquid solution as 2 puffs of daily dose (every morning) for 3 weeks. Functional magnetic resonance imaging (fMRI) scan pre- and post-administration. Oxytocin Intranasal Spray 24 International Unit (IU) Oxytocin Intranasal Spray 24 International Unit (24IU) Nasal spray of Oxytocin 24 International Unit (12IU) liquid solution as 2 puffs of daily dose (every morning) for 3 weeks. Functional magnetic resonance imaging (fMRI) scan pre- and post-administration. Oxytocin Intranasal Spray 24 International Unit (IU) Functional MRI Nasal spray of Oxytocin 24 International Unit (12IU) liquid solution as 2 puffs of daily dose (every morning) for 3 weeks. Functional magnetic resonance imaging (fMRI) scan pre- and post-administration.
- Primary Outcome Measures
Name Time Method Participant's Chronic Stress Levels in the Past Thirty Days Visit 1 (Baseline visit) and Visit 2 (Post-intervention visit). It will take about 5 minutes to complete at each time point. Participant's chronic ctress levels in the past thirty Days will be assessed by the Perceived Stress Scale total score. Scores can range from 0 to 40. Higher scores on this scale indicate higher levels of perceived stress (a worse outcome).
- Secondary Outcome Measures
Name Time Method Participant Quality of Life survey Visit 1 (Baseline visit) and Visit 2 (Post-intervention visit). It will take about 15 minutes to complete at each time point. Participant quality of life will be assessed by the Health Organization Quality of Life- Short version (WHO-QOL-BREF) which measures general perceptions about quality of life as four aspects of life: physical health, psychological health, social relationships, and environment. The secondary outcome that will be measured will be the participant ratings of the specific item, "How would you rate your quality of life?" The rating for this item ranges from 1 ('very poor') to 5 ('very good'), with higher scores indicating a better outcome.
Blood Oxygen Level Dependent (BOLD) responses in neural areas during the Affective Stroop task (AS) and Empathy and Theory of Mind(EmpaToM) task Visit 1 (Baseline visit) and Visit 2 (Post-intervention visit). It will take about 60 minutes to complete at each time point. Neural level changes will be measured by Functional Magnetic Resonance Imaging (fMRI).
Trial Locations
- Locations (1)
University of Nebraska Medical Center, Department of Psychiatry
🇺🇸Omaha, Nebraska, United States